Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Globerson-Levin A, Waks T, Eshhar Z.

Mol Ther. 2014 May;22(5):1029-38. doi: 10.1038/mt.2014.28. Epub 2014 Feb 27.

2.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
3.

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA.

J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447.

4.

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

5.

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z.

Gastroenterology. 2012 Nov;143(5):1375-84.e1-5. doi: 10.1053/j.gastro.2012.07.017. Epub 2012 Jul 20.

PMID:
22819865
6.

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.

Cancer Lett. 2017 May 1;393:52-59. doi: 10.1016/j.canlet.2017.02.015. Epub 2017 Feb 20.

PMID:
28223167
7.

Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12.

8.

Construction and evaluation of a novel humanized HER2-specific chimeric receptor.

Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y.

Breast Cancer Res. 2014 Jun 11;16(3):R61. doi: 10.1186/bcr3674.

9.

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.

10.

Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S.

J Immunother. 2014 Oct;37(8):407-15. doi: 10.1097/CJI.0000000000000052.

11.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.

12.

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.

Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.

13.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr.

Blood. 2012 Jan 19;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub 2011 Nov 23.

14.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.

Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.

15.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.

Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.

16.

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.

Wang W, Ma Y, Li J, Shi HS, Wang LQ, Guo FC, Zhang J, Li D, Mo BH, Wen F, Liu T, Liu YT, Wang YS, Wei YQ.

Gene Ther. 2013 Oct;20(10):970-8. doi: 10.1038/gt.2013.19. Epub 2013 May 2.

PMID:
23636245
17.

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Blood. 2002 Nov 1;100(9):3155-63. Erratum in: Blood. 2003 May 15;101(10):3808.

18.

Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.

Textor A, Listopad JJ, Wührmann LL, Perez C, Kruschinski A, Chmielewski M, Abken H, Blankenstein T, Charo J.

Cancer Res. 2014 Dec 1;74(23):6796-805. doi: 10.1158/0008-5472.CAN-14-0079. Epub 2014 Oct 8.

19.

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.

Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, Paolucci P, Dominici M.

Oncotarget. 2015 Sep 22;6(28):24884-94. doi: 10.18632/oncotarget.4670.

20.

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.

Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.

Supplemental Content

Support Center